Global Irritable Bowel Syndrome (IBS) Market Insights, Forecast to 2025

Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
Currently, the IBS treatment market is naïve and underpenetrated, with 4 products indicated for IBS in the market. These include the IBS-C therapies, Amitiza (lubiprostone, Sucampo/Takeda) and Linzess (linaclotide, Ironwood/Allergan/Astellas); and the IBS-D therapies, Lotronex (Sebela Pharmaceuticals) and Irribow (ramosetron, Astellas). Antidepressants and antibiotics (mainly Xifaxan [rifaximin], Valeant) are also used off-label to treat IBS.
The IBS treatment market is characterized by significant unmet needs, which include the need for products with improved efficacy, products for the treatment of the IBS-D and IBS-M subtypes, and products that effectively address IBS symptoms, such as abdominal pain and bloating, as well as the requirement for the improved diagnosis of IBS. As a result, there are significant opportunities in the uncrowded IBS therapeutics market.
The global Irritable Bowel Syndrome (IBS) market is valued at 2640 million US$ in 2018 and will reach 8650 million US$ by the end of 2025, growing at a CAGR of 16.0% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Irritable Bowel Syndrome (IBS) market based on company, product type, end user and key regions.

This report studies the global market size of Irritable Bowel Syndrome (IBS) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Irritable Bowel Syndrome (IBS) in these regions.
This research report categorizes the global Irritable Bowel Syndrome (IBS) market by top players/brands, region, type and end user. This report also studies the global Irritable Bowel Syndrome (IBS) market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Allergan
Valeant Pharmaceuticals
Takeda
Sucampo Pharmaceuticals
McNeil Consumer Healthcare
Sebela Pharmaceuticals
Astellas Pharmaceuticals
IM HealthScience

Market size by Product
IBS-D Drug
IBS-C Drug
Other
Market size by End User
Women
Men

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Irritable Bowel Syndrome (IBS) market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Irritable Bowel Syndrome (IBS) market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Irritable Bowel Syndrome (IBS) companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Irritable Bowel Syndrome (IBS) submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Irritable Bowel Syndrome (IBS) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Irritable Bowel Syndrome (IBS) market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions



This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

  • By product type
  • By End User/Applications
  • By Technology
  • By Region

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.

Please Select a Format

market Reports market Reports